Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radioactive treatment shows promise before prostate surgery

NCT ID NCT07208240

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 31 times

Summary

This study tests a new radioactive drug called Tb-PSMA given before surgery to remove the prostate in men with high-risk prostate cancer. The goal is to see if it is safe and helps improve surgical outcomes. About 20 participants will receive the drug and then undergo standard prostate removal surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beilinson Hospital

    RECRUITING

    Petah Tikva, Israel

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.